This article is for informational and educational purposes only and does not constitute medical advice. Chonluten is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Chonluten is a synthetic tripeptide composed of glutamic acid, aspartic acid, and glycine (Glu-Asp-Gly; single-letter: EDG), developed by the research group of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the peptide bioregulator class — a series of short synthetic peptides proposed to modulate gene expression in a tissue-specific manner by interacting with DNA regulatory elements. Chonluten was characterized as the bronchial/respiratory epithelium bioregulator of the series and has also been studied in the context of intestinal mucosal tissue. Cell-based and organotypic tissue-culture studies, conducted predominantly within the Khavinson laboratory, have examined associations between EDG exposure and markers of epithelial cell proliferation, antioxidant enzyme activity, stress-response gene expression, and inflammatory mediators. Molecular docking analyses have additionally examined EDG’s proposed interactions with gene promoter sequences. No peer-reviewed clinical trials evaluating Chonluten in human subjects have been published; all available mechanistic and pharmacological evidence derives from cell-based assays, organotypic cultures, animal studies, and in silico analyses.
1. Background
1.1 Peptide Bioregulators — The Khavinson Class
The peptide bioregulator class was developed from the 1970s onward by Vladimir Khavinson and colleagues at the Institute of Bioregulation and Gerontology in St. Petersburg, on the hypothesis that short organ-derived peptides could regulate gene expression in a tissue-targeted manner. Chonluten is unusual within the series in being assigned to two epithelial systems rather than one, characterized as a bioregulator for bronchial and respiratory epithelium and studied additionally in intestinal mucosal tissue.
The class includes a range of named compounds, each proposed to target specific tissue types: Epitalon (Ala-Glu-Asp-Gly) for the pineal gland, Bronchogen (Ala-Glu-Asp-Leu) for bronchial tissue, Cortagen (Ala-Glu-Asp-Pro) for the nervous system, Vilon (Lys-Glu) for immune regulation, and Chonluten (Glu-Asp-Gly) for the bronchial epithelium and mucosal tissue, among others. Notably, Chonluten’s EDG sequence is identical to the C-terminal three residues of Epitalon (AEDG), differing only by the absence of the N-terminal alanine. The biological rationale for tissue specificity — why a tripeptide would preferentially influence gene expression in one tissue over another following systemic administration — has not been mechanistically established through independent research [2].
1.2 The Bronchial Epithelium and Mucosal Tissue
The respiratory tract is lined by a specialized epithelium that forms the primary barrier between inhaled air and the underlying tissue. Bronchial epithelial cells perform mucociliary clearance, secrete protective mucins and antimicrobial factors, and maintain tight-junction barrier integrity. This epithelium is continuously exposed to oxidative stress, particulates, and pathogens, and its barrier and regenerative capacity decline with age — a factor in age-associated respiratory vulnerability [4]. The intestinal mucosa performs an analogous barrier role in the gut, and both tissues share features of continuous epithelial turnover and barrier maintenance.
Chonluten’s development within the Khavinson group was based on the hypothesis that a short peptide modeled on bronchial epithelial tissue-derived sequences could support gene expression programs relevant to respiratory and mucosal epithelial function, barrier integrity, and resistance to oxidative and inflammatory stress. The specific relationship between the EDG sequence and endogenous bronchial peptide content has not been independently characterized.
1.3 Historical and Research Context
The Chonluten record rests on organotypic tissue-culture work from the Khavinson group with N. I. Chalisova and colleagues [3], published predominantly in Russian-language journals, together with reports of antioxidant and SOD-related activity. Because the compound is characterized across two distinct mucosal tissues, the available literature is spread thinner per tissue than the overall volume suggests, and no independent laboratory has published a replication in either [1].
2. Molecular Structure
Chonluten is a tripeptide with the sequence Glu-Asp-Gly, abbreviated in single-letter code as EDG. At three residues it is among the shortest peptides in the research peptide class, alongside Pinealon (EDR) and Cartalax (AED).
| Property | Detail |
|---|---|
| Full name | L-α-Glutamyl-L-α-aspartyl-glycine |
| Sequence (single-letter) | EDG |
| Length | 3 amino acids (tripeptide) |
| Molecular formula | C₁₁H₁₇N₃O₈ |
| Molecular weight | ~319 Da |
| Net charge (physiological pH) | Acidic: two acidic residues (Glu, Asp) and one small neutral (Gly) |
| Relationship to Epitalon | Identical to the C-terminal tripeptide of Epitalon (AEDG) |
| Post-translational modifications | None; fully synthetic |
| Water solubility | High |
| Class | Peptide bioregulator (Khavinson group) |
Unlike Pinealon (EDR), which carries a basic arginine at its C-terminus, Chonluten terminates in glycine — the smallest amino acid, with only a hydrogen atom as its side chain. The molecule therefore carries a net negative charge at physiological pH from its two acidic residues. In the Khavinson group’s proposed DNA-binding framework, the acidic glutamate and aspartate side chains are proposed to participate in sequence-specific contacts with nucleotide bases, while the compact glycine terminus is proposed to permit close approach to the DNA groove. Whether the EDG tripeptide interacts with genomic DNA in the manner proposed — and whether such interaction, if it occurs, is sufficient to alter transcription at physiologically meaningful concentrations — has not been independently established [2].
3. Proposed Mechanisms
The mechanisms below have been proposed in cell-based, organotypic culture, animal model, and computational studies. None has been confirmed in controlled human interventional research. All mechanistic claims originate predominantly from the Khavinson group.
4. Key Research Findings
| Research Area | Evidence Level | Best Available Evidence |
|---|---|---|
| Bronchial epithelial regulation | Limited Cell-based / organotypic |
Khavinson & Chalisova group; tissue-culture studies |
| DNA interaction / gene expression | Limited In silico + cell-based |
Tarnovskaya et al. 2014 (Adv Gerontol) |
| Antioxidant / stress-response (SOD, HSP70) | Limited Cell-based only |
Khavinson group; multiple studies |
| Anti-inflammatory (COX-2, TNF-α) | Limited Cell-based only |
Limited published literature |
| Intestinal / mucosal barrier | Limited Cell-based, animal models |
Limited; predominantly originating laboratory |
| Respiratory function (in vivo / human) | Limited None published |
No peer-reviewed clinical trials identified |
4.1 Bronchial Epithelium and Organotypic Culture Studies
Research within the Khavinson group, including organotypic tissue-culture work conducted with Chalisova and colleagues, has reported that EDG tripeptide exposure was associated with increased indices of cell proliferation in bronchial and respiratory tissue preparations relative to untreated controls [3]. These cell-based and tissue-culture findings represent the primary experimental basis for Chonluten’s proposed role in supporting bronchial epithelial regenerative capacity and form much of the characterization of the compound. The specific effect magnitudes and experimental conditions have not been fully characterized in peer-reviewed literature accessible through international databases.
Schematic representation based on approximate directional findings reported for EDG in bronchial/respiratory tissue-culture models [3]. Values are illustrative approximations and should not be interpreted as precise experimental data. Not derived from human or in vivo studies.
4.2 DNA Interaction and Gene Regulatory Mechanism
Tarnovskaya et al. (2014) described the mechanistic framework by which short bioregulator peptides are proposed to interact with DNA. Using molecular modeling and docking analyses, the group proposed that short peptides bind to specific nucleotide sequences in promoter regions of target genes, with charged residues forming electrostatic contacts with the DNA phosphate backbone and side chains participating in sequence-specific interactions within the major groove [2]. For EDG, the two acidic residues are proposed to contribute sequence-specific contacts, while the minimal glycine side chain is proposed to allow close approach to the DNA surface.
Different short peptide sequences were reported to show preferential in silico affinity for different DNA nucleotide motifs, providing the proposed theoretical basis for tissue-specific gene regulation by different named bioregulators. The applicability of these in silico binding affinities to transcriptional regulation in living cells — where peptides must compete with histones, transcription factors, and other DNA-binding proteins at far higher effective concentrations — has not been independently verified by structural or biochemical methods such as ChIP, EMSA, or DNase I footprinting.
4.3 Antioxidant, Stress-Response, and Inflammatory Markers
Cell-based studies have reported associations between Chonluten exposure and a panel of molecular markers relevant to epithelial stress biology: increased activity of the antioxidant enzyme superoxide dismutase (SOD), modulation of the stress-response proteins heat-shock protein 70 (HSP70) and the immediate-early transcription factor c-Fos, and changes in the inflammatory mediators cyclooxygenase-2 (COX-2) and tumor necrosis factor-alpha (TNF-α). Taken together, these marker-level observations have been interpreted by the originating group as consistent with a cytoprotective, anti-inflammatory profile for the peptide in epithelial tissue.
As with the broader bioregulator literature, these findings are marker-level and preliminary. A change in the activity or expression of a stress-response or inflammatory marker in cultured cells does not establish a meaningful functional effect on respiratory or intestinal tissue in a living organism, and none of these observations has been replicated by independent laboratories or extended into controlled in vivo endpoints.
5. Evidence Status
| Evidence Type | Current Status |
|---|---|
| Organotypic mucosal tissue-culture studies | Published (Khavinson and Chalisova group; predominantly Russian-language journals) |
| Bronchial epithelial regulation | Reported at marker level in cell and explant preparations |
| Intestinal epithelial regulation | Reported in the same literature; the dual-tissue claim rests on both sets |
| Antioxidant / SOD-related pathway effects | Reported by the originating group; enzyme-level mechanism not independently characterized |
| In silico docking to gene promoter sequences | Published; predicted binding geometry, not experimentally confirmed |
| Barrier function measured directly (permeability, TEER) | Not published; barrier claims are inferred from expression markers |
| Human respiratory or gastrointestinal outcomes | No published trial at any phase |
What We Still Don’t Know
- Whether the proposed DNA-binding mechanism operates in living cells: The in silico docking analyses propose a specific interaction between EDG and gene promoter sequences, but whether this peptide at pharmacologically achievable intracellular concentrations actually binds chromatin-associated DNA in intact bronchial or intestinal cells has not been demonstrated by independent investigators using established biochemical methods.
- Whether tissue specificity exists and how it would operate: The classification of Chonluten as a bronchial/mucosal bioregulator implies tissue-preferential activity. No published pharmacokinetic study has demonstrated preferential distribution of EDG to respiratory or intestinal epithelium relative to other tissues following systemic administration.
- Whether the marker-level effects translate to function: Reported changes in proliferation indices, SOD, HSP70, c-Fos, COX-2, and TNF-α are marker-level observations in cultured cells. Whether they correspond to any meaningful change in respiratory or intestinal tissue function in a whole organism is unknown.
- How EDG relates functionally to Epitalon: Because EDG is the C-terminal tripeptide of Epitalon (AEDG), whether the two peptides share overlapping activity, and what the N-terminal alanine contributes, has not been experimentally clarified in the independent literature.
- Human safety and pharmacokinetics: No published phase 1 trial characterizes the safety, tolerability, half-life, or target-tissue distribution of Chonluten in humans. As a tripeptide, it would be expected to undergo rapid hydrolysis by plasma and tissue peptidases, but human pharmacokinetic data are absent.
- Effective dose and route of administration in any in vivo context: Dose-response data in animal models and the pharmacologically active concentration range in living respiratory or intestinal tissue are not characterized in the independent literature.
6. Limitations of Current Research
References
- Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Basel: Karger; 2005. ISBN 3-8055-7833-7.
- Tarnovskaya SI, Khavinson VKh, Linkova NS, Pronyaeva VE, Kolchina NV, Tendler SM. “Mechanism of Short Peptides Interaction with DNA.” Advances in Gerontology. 2014;27(4):706–714.
- Chalisova NI, Linkova NS, Zhekalov AN, Orlova AO, Ryzhak GA, Khavinson VKh. “Short peptides stimulate cell renewal in organotypic tissue cultures during aging.” Advances in Gerontology. 2015;5(3):176–181. doi:10.1134/S2079057015030029
- Ganesan S, Comstock AT, Sajjan US. “Barrier function of airway tract epithelium.” Tissue Barriers. 2013;1(4):e24997. doi:10.4161/tisb.24997